PROKIDNEY CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.71 USD | +10.09% |
|
+10.09% | +108.43% |
| May. 28 | Transcript : ProKidney Corp. - Special Call | |
| May. 10 | ProKidney Q1 Loss Unchanged From Year Earlier | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 222M |
|---|---|---|---|---|---|
| Net income 2024 * | -146M | Net income 2025 * | -43M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 193M | Net cash position 2025 * | 310M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.72
x | P/E ratio 2025 * |
-4.85
x | Employees | 163 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.3% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProKidney Corp.
More recommendations
More press releases
| 1 day | +10.09% | ||
| 1 week | +10.09% | ||
| Current month | +6.61% | ||
| 1 month | +79.66% | ||
| 3 months | +127.61% | ||
| 6 months | +120.83% | ||
| Current year | +108.43% |
1 week
3.27
4.35
1 month
2.034.44
Current year
1.184.44
1 year
1.1213.51
3 years
1.1214.19
5 years
1.1214.19
10 years
1.1214.19
| Managers | Title | Age | Since |
|---|---|---|---|
Bruce Culleton
CEO | Chief Executive Officer | 57 | 23-07-16 |
James Coulston
DFI | Director of Finance/CFO | 48 | 21-12-31 |
Joseph Stavas
CTO | Chief Tech/Sci/R&D Officer | 69 | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 21-12-31 |
Brian Pereira
BRD | Director/Board Member | 65 | 21-12-31 |
John Maraganore
BRD | Director/Board Member | 60 | 22-08-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 3.48 | -17.14% | 565,393 |
| 24-05-30 | 4.2 | +6.06% | 675,503 |
| 24-05-29 | 3.96 | +6.74% | 1,178,068 |
| 24-05-28 | 3.71 | +10.09% | 594,957 |
| 24-05-24 | 3.37 | -3.99% | 317,888 |
End-of-day quote Nasdaq, May 27, 2024
More quotes
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patientâs own cells isolated from the patient intended for treatment. The Companyâs lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patientâs diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patientâs own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participantâs own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Calendar
2024-06-03
- Jefferies Global Healthcare Conference
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.48
USD
Average target price
6.333
USD
Spread / Average Target
+81.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +108.43% | 268M | |
| +43.36% | 58.06B | |
| -5.31% | 40.53B | |
| +37.52% | 38.99B | |
| +14.75% | 26.7B | |
| -12.56% | 26.56B | |
| -22.45% | 18.98B | |
| +0.04% | 12.17B | |
| +25.12% | 12B | |
| +26.04% | 11.92B |
- Stock Market
- Equities
- PROK Stock
